Research To Practice

・

頻道・共 10 個節目

科學

科學

每月更新
科學

科學

每週更新
科學

科學

每週更新
科學

科學

每週更新
科學

科學

每週更新
科學

科學

每週更新
科學

科學

每月更新兩次

7月8日

Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics: Introduction (00:00)Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10) CME information and select publications
7月25日

Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00)Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications
7月29日

For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics: Introduction (00:00)Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)Adjuvant CDK4/6 Inhibitor Therapy (17:14)Practical Considerations with CDK4/6 Inhibitors (29:57)Monitoring and Management of Cytopenias (42:02)CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)Management of Gastrointestinal Adverse Events (1:03:47)CDK4/6 Inhibitors in Unique Populations (1:10:41)Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48) CME information and select publications
7月21日

EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (00:00)Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46) CME information and select publications
6月29日

HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00)Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00) CME information and select publications
7月18日

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics: Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03) CME information and select publications
7月23日

For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics: Introduction (00:00)Overview of Ovarian Cancer (OC) (2:12)Role of PARP Inhibitors in Advanced OC (4:56)Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)Role of Relacorilant in Advanced OC (57:08)Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12) NCPD information and select publications
7月13日

Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics: Introduction: ODAC — April 30, 2026 (00:00)Adjuvant CDK4/6 Inhibitors (13:03)Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)Premenopausal Patients (30:52)Duration of Adjuvant Endocrine Treatment (38:44)Genomic Predictors of Chemotherapy Benefit (47:19)Neoadjuvant Treatment (55:13) CME information and select publications
6月23日

HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics: Introduction (0:00)Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51) CME information and select publications
6月30日

Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00)Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications

CME education for oncology clinicians. Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.